The Australian rise of esomeprazole -Was expenditure on samples a contributor?

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 1, 2009, Pages 62-68

  Kyle, Gregory J ^a   Nissen, Lisa M ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Influence; Marketing; Medicines; Prescription; Samples

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; ANTIULCER AGENT; OMEPRAZOLE;

ARTICLE; AUSTRALIA; CONTROLLED STUDY; COST; COST CONTROL; DRUG INDUSTRY; DRUG MARKETING; DRUG USE; DRUG UTILIZATION; ECONOMIC EVALUATION; INVESTMENT; PRESCRIPTION; PRIORITY JOURNAL; SAMPLING; TREND STUDY; CLINICAL PRACTICE; DRUG COST; ECONOMICS; HEALTH INSURANCE; HUMAN; INSURANCE; MARKETING; METHODOLOGY;

ANTI-ULCER AGENTS; AUSTRALIA; DRUG COSTS; DRUG INDUSTRY; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MARKETING; OMEPRAZOLE; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS;

EID: 59049088069     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1685     Document Type: Article

References (36)

1. Forsyth P. Marketing Stripped Bare: An Insider's Guide to the Secret Rules. Kogan Page: London; Sterling, VA, 2003.
2. Gonul FF, Carter F, Petrova E, et al. Promotion of prescription drugs and its impact on physicians' choice behavior. J Market 2001; 65: 79-90.
3. Paich M, Peck C, Valant J. Pharmaceutical Product Strategy: Using Dynamic Modeling for Effective Brand Planning. Interpharm/CRC: Boca Raton, FL, 2005.
4. Blackett T, Robins R (eds). Brand Medicine: The Role of Branding in the Pharmaceutical Industry. Palgrave: New York, 2001.
5. Oldani MJ. Thick prescriptions: toward an interpretation of pharmaceutical sales practices. Med Anthropol Q 2004; 18: 325-356 DOI: 10.1525/maq.2004.18.3.325
6. Wazana A. Physicians and the pharmaceutical industry - is a gift ever just a gift? JAMA 2000; 283: 373-380.
7. Hall K, Tett SE, Nissen LM. Perceptions of the influence of prescription medicine samples on prescribing by family physicians. Med Care 2006; 44: 383-387. DOI: 10.1097/01.mlr.0000204017.71426.53
8. Spurling G, Kyle GJ. Is your sample cupboard relevant to your general practice? Aust Fam Physician 2007; 36: 187-188, 192.
9. Department of Health and Ageing. About the PBS. Commonwealth of Australia, Canberra; 2004. http://www.health.gov.au/internet/wcms/ publishing.nsf/content/about%20the%20pbs-1 [accessed 13 March 2006].
10. Pharmaceutical Pricing Section (Pharmaceutical Benefits Branch). Expenditure and Prescriptions Twelve Months to 30 June 2006. Commomwealth of Australia, Canberra; 2006. http://www.health.gov.au/ internet/main/publishing.nsf/Content/3CC2D4DF821FE5ADCA2570F40005B9B1/ $File/Full%20book%202005-06.pdf [accessed 17 March 2007].
11. Axford L. E-mail: Cegedim Strategic Data GP Promotional Audit Data 2002-2006. Kyle GJ. Sydney 2006; 1.
12. Cegedim Strategic Data. Cegedim Strategic Data (CAM) GP Promotional Audit Data 2002-2006. Sydney, December, 2006.
13. Medicare Australia. Medicare Australia Statistical Reporting. Australian Government: Canberra, 2007. http://www.medicareaustralia.gov.au/providers/health_statistics/ statistical_reporting.htm [accessed 25 September 2007].
14. Medicare Australia. Pharmaceutical Benefits Schedule Item Statistics. Australian Government: Canberra, ACT, Australia, 2008 [accessed 1 May 2008].
15. Carling PC, Fung T, Coldiron JS. Parenteral antibiotic use in acute-care hospitals: a standardized analysis of fourteen institutions. Clin Infect Dis 1999; 29: 1189-1196. DOI: 10.1086/313431
16. World Health Organisation. Criteria for medicinal drug promotion. World Health Organisation: Oslo, Norway, 2007. http://www.whocc.no/ atcddd/ [accessed 25 October 2007].
17. Australian Bureau of Statistics. Australian Demographic Statistics (Cat No. 3101.0); 2008 [cited 17 March]; Available from: www.abs.gov.au
18. Clow KE, Baack D. Integrated Advertising, Promotion, & Marketing Communications (2nd edn). Pearson: Upper Saddle River, NJ, 2004.
19. Shimp TA. Advertising, Promotion & Supplemental Aspects of Integrated Marketing Communications (6th edn). Thomson South-Western: Mason, OH, 2003.
20. Summers J. Essentials of Marketing (2nd edn). Thomson: South Melbourne, 2005.
21. Blackwell RD, Miniard PW, Engel JF. Consumer Behavior (9th edn). Harcourt College Publishers: Fort Worth, TX, 2001.
22. IMS Health. Top Ten Global Therapeutic Classes 2007. IMS Health, 2008. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/ StaticFile/Top_Line_Data/Top10GlobalTherapyClasses.pdf [accessed 20 August 2008].
23. Angell M. The Truth About the Drug Companies. Scribe Publications: Carlton North, Vic, 2005.
24. Moynihan R, Cassels A. Selling Sickness: How Drug Companies are Turning Us All Into Patients. Allen & Unwin: Crows Nest, 2005.
25. IMS Health. Total U.S. Promotional Spend by Type, 2004. IMS Health, 2005. http://www.imshealth.com/ims/portal/front/articleC/ 0,2777,6319_49695992_75406357,00.html [accessed 18 May 2006].
26. Productivity Commission. International Pharmaceutical Price Differences (Research Report). Commonwealth of Australia: Canberra, 2001.
27. Sweeny K. Australian Pharmaceutical Pricing in a Global Context. Victoria University of Technology: Melbourne, 2004.
28. Zweifler J, Hughes S, Schafer S, et al. Are sample medicines hurting the uninsured? J Am Board Fam Pract 2002; 15: 361-366.
29. Findlay S. Do ads really drive pharmaceutical sales? The true effects of DTC advertising remain a mystery. Mark Health Serv 2002; 22: 20-25.
30. Mintzes B. Direct-to-Consumer Advertising of Prescription Drugs in Canada. What Are the Public Health Implications? Health Council of Canada: Toronto, 2006.
31. Wilkes MS, Bell RA, Kravitz RL. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff (Millwood) 2000; 19: 110-128.
32. IMS Health. Top-Line Industry Data. IMS Health, 2007. http://www.imshealth.com/ims/portal/front/indexC/0,2773, 6599_5264_0,00.html [accessed 20 May 2008].
33. Cain DM, Detsky AS. Everyone's a little bit biased (even physicians). JAMA 2008; 299: 2893-2895.
34. Faunce TA. Submission to Productivity Commission Inquiry Impact of Advances in Medical Technology on Healthcare Expenditure in Australia. The Australian National University: Canberra, 2005. http://www.law.anu.edu.au/StaffUploads/236-subProdComm060.pdf [accessed 21 January 2008].
35. Harvey KJ. The pharmaceutical benefits scheme under threat. Health Issues 2002; 71: 11-16.
36. Primary Health Care Research & Information Service. Key Division of General Practice Characteristics 2005-2006. Primary Health Care Research & Information Service, 2007. http://www.phcris.org.au/products/asd/ keycharacteristic/KeyDGPstatistics.xls [accessed 20 May 2008].